SPOTLIGHT -
EP. 1: Introduction: Exploration of Nab-Paclitaxel in NSCLC
EP. 2: Nab-Paclitaxel in Non-Small Cell Lung Cancer
EP. 3: Maintenance Nab-Paclitaxel in Squamous NSCLC
EP. 4: Subgroup Analyses for Nab-Paclitaxel in NSCLC
EP. 5: Next-Generation EGFR Inhibitors in NSCLC
EP. 6: AZD9291 and Rociletinib in T790M-Mutant NSCLC
EP. 7: Afatinib Plus Cetuximab in Resistant NSCLC
EP. 8: Frontline ALK, EGFR Inhibition in NSCLC
EP. 9: Next-Generation ALK Inhibitors in NSCLC
EP. 10: Utilizing Next-Generation ALK Inhibitors in NSCLC
EP. 11: Efficacy of Next-Generation ALK Inhibitors
EP. 12: PD-1 Inhibition in Lung Cancer
EP. 13: Nivolumab in Non-Small Cell Lung Cancer
EP. 14: Multiple PD-1/PD-L1 Agents in Lung Cancer
EP. 15: PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings
EP. 16: Role of Maintenance Therapy in NSCLC
EP. 17: Maintenance Therapy Clinical Trials for NSCLC
EP. 18: PointBreak and AVAPERL Studies in NSCLC
EP. 19: Emerging Therapies in Non-Small Cell Lung Cancer
EP. 20: Novel Angiogenesis Inhibitors in NSCLC
EP. 21: Potential New Biomarkers in Lung Cancer
EP. 22: Conclusion: Addressing Unmet Needs in Lung Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
